NCT00563446

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Hospital Authority, Hong Kong · Other Government
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows dosing at extended intervals and less frequent injection. The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.

Conditions

• Anemia
• Kidney Failure, Chronic
• Peritoneal Dialysis, Continuous Ambulatory

Interventions

Type	Name	Description
DRUG	Darbepoetin alfa

Timeline

• Start date: 2005-07-01
• Completion: 2006-05-01
• First posted: 2007-11-26
• Last updated: 2011-06-16

Locations

1 site across 1 country: China